CN1381465A - 抗菌肽葛佬素的基因构建、制备方法及用途 - Google Patents
抗菌肽葛佬素的基因构建、制备方法及用途 Download PDFInfo
- Publication number
- CN1381465A CN1381465A CN 01110740 CN01110740A CN1381465A CN 1381465 A CN1381465 A CN 1381465A CN 01110740 CN01110740 CN 01110740 CN 01110740 A CN01110740 A CN 01110740A CN 1381465 A CN1381465 A CN 1381465A
- Authority
- CN
- China
- Prior art keywords
- adopts
- gloverin
- seconds
- product
- cdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 28
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 24
- 230000008569 process Effects 0.000 title abstract description 4
- 239000002299 complementary DNA Substances 0.000 claims abstract description 54
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- 101710086289 Attacin Proteins 0.000 claims abstract description 10
- 108010006314 gloverin Proteins 0.000 claims description 76
- 239000000047 product Substances 0.000 claims description 37
- 235000018102 proteins Nutrition 0.000 claims description 20
- 108020004705 Codon Proteins 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 230000004087 circulation Effects 0.000 claims description 12
- 230000029087 digestion Effects 0.000 claims description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 9
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 6
- 208000037487 Endotoxemia Diseases 0.000 claims description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 239000013599 cloning vector Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 238000013467 fragmentation Methods 0.000 claims description 4
- 238000006062 fragmentation reaction Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 108091008146 restriction endonucleases Proteins 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 108020005038 Terminator Codon Proteins 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 2
- 239000006035 Tryptophane Substances 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000003752 polymerase chain reaction Methods 0.000 abstract description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 241000255789 Bombyx mori Species 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002346 endotoxic effect Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 231100000284 endotoxic Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101000937323 Trichoplusia ni Attacin-A Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01110740 CN1237073C (zh) | 2001-04-18 | 2001-04-18 | 抗菌肽葛佬素的基因构建、制备方法及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01110740 CN1237073C (zh) | 2001-04-18 | 2001-04-18 | 抗菌肽葛佬素的基因构建、制备方法及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1381465A true CN1381465A (zh) | 2002-11-27 |
CN1237073C CN1237073C (zh) | 2006-01-18 |
Family
ID=4658803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 01110740 Expired - Fee Related CN1237073C (zh) | 2001-04-18 | 2001-04-18 | 抗菌肽葛佬素的基因构建、制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1237073C (zh) |
-
2001
- 2001-04-18 CN CN 01110740 patent/CN1237073C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1237073C (zh) | 2006-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU676891B2 (en) | Pharmaceutical containing the P40 subunit of interleukin 12 | |
US20190216898A1 (en) | Interleukin Combination and Use Thereof | |
JPS60100599A (ja) | 修飾インタ−フエロン | |
JP2007181465A (ja) | マクロファージ炎症蛋白変種をコードするポリヌクレオチド | |
JPH025760B2 (zh) | ||
CN101967196A (zh) | 一种干扰素融合蛋白及其制备和应用 | |
AU2010203446B2 (en) | Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22 | |
JP2002522508A5 (zh) | ||
KR101444261B1 (ko) | 왕지네로부터 분리한 신규 스콜로펜드라신ⅰ펩타이드 및 그의 조성물 | |
HU205617B (en) | Process for producing neturophyl-activating factor, gene coding this and pharmaceutical composition | |
CN116836233B (zh) | 抗炎活性多肽及其应用 | |
JP2000063400A (ja) | 抗菌ペプチド及びこれを有効成分とする抗菌剤 | |
CN101514229A (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物 | |
CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
KR101995768B1 (ko) | 신규 펩타이드 및 그 용도 | |
CN107987144B (zh) | 一种蜈蚣多肽SLP_SsTx及其编码基因和应用 | |
CN1237073C (zh) | 抗菌肽葛佬素的基因构建、制备方法及用途 | |
EP1176870A2 (en) | Tgf-alpha polypeptides, functional fragments and methods of use therefor | |
CA2284548A1 (en) | The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf) | |
CN102816209A (zh) | 一种趋化素衍生肽及其表达基因和应用 | |
US5440022A (en) | Hepatokine and methods for its use | |
KR101025352B1 (ko) | 생리활성 복합체 | |
JP2005508356A5 (zh) | ||
WO1994019462A1 (fr) | Facteurs de croissance de la famille de l'harp, procede d'obtention et applications | |
WO2002081519A2 (en) | Ifn-thy fusion protein,dna coding therefore,its preparation and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: MILITARY MEDICAL UNIV NO.3, P.L.A. Free format text: FORMER OWNER: ZHOU HONG; ZHENG JIANG Effective date: 20060224 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060224 Address after: Zheng Jie gaotanyan Shapingba District of Chongqing City, Sichuan Province, No. 30 400038 Patentee after: Third Military Medical University, Chinese People's Liberation Army Address before: Chongqing city Shapingba street 400038 gaotanyan of Southwest Hospital burn No. 30 Co-patentee before: Zheng Jiang Patentee before: Zhou Hong |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |